Product Name | GLCTLVAML |
Product Quantity | 4mg |
Catalog Number | LT8259 |
Category | EBV_ICP27 |
Sequence | GLCTLVAML |
Purity | >95% |
Product Description | The GLCTLVAML peptide corresponds to an epitope from the BMLF1 protein of Epstein-Barr virus, also known as ICP27 homolog. Presented by HLA-A*02:01, it is recognized by CD8+ T cells and is instrumental in studying EBV-specific cytotoxic T lymphocyte responses, particularly during the lytic phase of infection. This epitope is valuable in monitoring immune responses and developing targeted immunotherapies against EBV-associated diseases. |
Scientific Background | GLCTLVAML is a 9-residue synthetic peptide with the sequence Gly-Leu-Cys-Thr-Leu-Val-Ala-Met-Leu. The sequence contains 1 cysteine residue, providing potential thiol/disulfide chemistry when the thiol is available; has a relatively high hydrophobic-residue fraction that can influence aqueous solubility and surface adsorption. These sequence-derived properties describe the reagent chemically; no specific receptor, enzyme, pathway, disease association, or biological activity is assigned without product-specific experimental evidence. |
Research Applications | - thiol-selective conjugation or immobilization studies
- LC-MS/HPLC analytical method development
- sequence-specific assay controls
|
Experimental Notes | Sequence-derived chemical properties support reagent selection and experimental planning but do not establish biological function. Solubility, aggregation, adsorption, conjugation efficiency, and assay performance should be validated under the intended experimental conditions. |
